CORT
Corcept Therapeutics Incorporated
NASDAQ · USHealthcareBiotechnology
$91.57+1.16%
Price as of Jul 20, 2026
CORT growth
Corcept Therapeutics Incorporated growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +12.2%
- EBITDA
- -88.7%
- EBIT
- —
- EPS
- -64.6%
- Free cash flow
- -32.4%
- Operating cash flow
- -33.1%
Forward estimates
- Revenue
- +33.4%
- EBITDA
- +1570.5%
- EPS
- +109.7%
Three-year CAGR
- Revenue
- +23.7%
- EBITDA
- -16.5%
- EBIT
- -26.5%
- Net income
- -0.6%
- EPS
- +0.0%
- Free cash flow
- +5.7%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.